Nephroapp
Exam Cases MCQ Bank

Search

Find tools, topics, and resources

Welcome to Nephroapp
Sign in to keep your progress and bookmarks.
Log in Create account
Explore
Exam cases MCQ Bank Topics Plans and pricing
App
Explore NephroApp
Exam Cases MCQ Bank

Study

Exam cases
MCQ Bank
Fast Recaps
Plans and pricing
‹ Fast Recaps

🦴 CKD & Bone-Mineral

9 Fast Recaps

💧 Peritoneal Dialysis ⚡ Electrolytes & Acid–Base 🩸 Hemodialysis & Access 🏥 CRRT / ICU 💓 Hypertension 🫀 Transplant 🔬 Glomerular 🪨 Tubular & Stones ⭐ Special Topics 🚨 Acute Kidney Injury
CKD-MBD / hyperparathyroidism / binders Diabetic kidney disease (SGLT2/finerenone/GLP1) CKD progression — 4-pillar therapy Metabolic acidosis in CKD (bicarbonate/diet) Anemia of CKD (ESA / HIF / iron) ESRD / CKD5 weight loss work-up (pre-dialysis) Conservative kidney management and dialysis withdrawal CKD: KDIGO 2024 definition, CGA classification, screening, work-up and referral Drug dosing in CKD and dialysis
11

CKD-MBD / hyperparathyroidism / binders

Open the full topic →
Fast Recap · 7 stops

CKD-MBD at a glance

Phosphate retention, low calcitriol and high FGF23 drive secondary hyperparathyroidism. Fix phosphate, calcium and vitamin D first; then lower PTH, not to normal.

  1. P P P FGF23 Phosphate retention Falling GFR retains phosphate; FGF23 rises early.
  2. Ca Calcitriol and calcium fall 1-alpha-hydroxylase suppressed; calcium drops.
  3. PTH Parathyroid hyperplasia PTH rises; over-suppression later: adynamic bone.
  1. 1

    Stop 1 · Diagnosis

    Biochemical assessment

    Ca, PO4, intact PTH, ALP, 25-OH D: serial, read together (KDIGO 2017 4.1.1).

    PO4 Ca PTH
    Check 1

    Corrected calcium

    Albumin-corrected or ionized calcium before any PTH-lowering drug.

    Check 2

    History and examination

    Bone pain, fracture, pruritus, painful skin lesions; diet, binder adherence. Exam: fracture, vascular calcification, skin necrosis.

    High PO4, low or normal Ca, high PTH
    Classic triad: secondary hyperparathyroidism.
    High Ca, high or inappropriately normal PTH, dialysis
    Tertiary HPT: cinacalcet; parathyroidectomy if refractory.
    PTH persistently below about 2× assay ULN, low ALP
    Adynamic bone: over-suppressed PTH (stop 7).
    Red flag

    Calciphylaxis: painful skin necrosis, high mortality; with raised PTH, urgent parathyroidectomy. Also: severe hyperphosphataemia with vascular or soft-tissue calcification.

    Memory hook
    PO4 ↑phosphate Ca ↓/=calcium PTH ↑hormone FGF23rises first Trendnot one value

    “Up, down, up, then read the trend.” Trends, not single values (1C).

  2. 2

    Stop 2 · Monitoring

    Monitoring and bone assessment

    Subscribers only

Unlock the other 6 stops

Every drawing, memory hook and exam trap, the pocket check, the spoken answer, the viva questions and every section of this topic.

  1. Phosphate control
  2. Vitamin D therapy
  3. PTH target and calcimimetics
  4. Indications for parathyroidectomy
  5. Hungry bone syndrome and adynamic bone disease
See the plans →
12

Diabetic kidney disease (SGLT2/finerenone/GLP1)

Open the full topic →
Fast Recap · seven stops

Diabetic kidney disease at a glance

Clinical diagnosis in typical cases, no biopsy. Layer kidney protection; watch two SGLT2i traps: eGFR dip, euglycaemic DKA.

  1. Clinical diagnosis Typical features: no biopsy (stop 1).
  2. ACEi / ARB SGLT2i finerenone GLP-1 RA Four pillars Triple standard, quadruple emerging (stops 2–6).
  3. 9 glucose 4.2 ketones Two SGLT2i traps Expected eGFR dip; DKA with normal glucose.
  1. 1

    Stop 1 · Diagnosis

    Diagnostic criteria and indications for biopsy

    Typical DKD: clinical diagnosis. Biopsy only if atypical; small kidneys make it unwise.

    >10 y small and echogenic

    Typical DKD: no biopsy

    • Long-standing diabetes, usually >10 years
    • Diabetic retinopathy (correlates with nephropathy)
    • Gradual, progressive proteinuria
    • Small, echogenic kidneys

    Atypical features: biopsy

    • No retinopathy, especially in type 1 diabetes
    • Active sediment: red cell casts, dysmorphic RBCs
    • Rapid GFR decline
    • Sudden heavy or nephrotic-range proteinuria
    • Short diabetes duration, heavy proteinuria

    Alternative or superimposed: membranous, FSGS, IgA nephropathy, minimal change disease.

    Baseline work-up

    • Urine ACR or PCR, trended
    • eGFR trend
    • Fundoscopy
    • Renal ultrasound
    • Urine microscopy: active sediment
    • HbA1c, lipids, potassium
    Memory hook
    Longdiabetes Eyeretinopathy Slowproteinuria Smallkidneys Nobiopsy

    All four: “advanced diabetic nephropathy”.

    Exam trap

    No retinopathy does not exclude DKD in type 2; strong biopsy trigger in type 1. Don’t biopsy a typical case for proteinuria alone.

  2. 2

    Stop 2 · Treatment

    RAS blockade

    Subscribers only

Unlock the other 6 stops

Every drawing, memory hook and exam trap, the pocket check, the spoken answer, the viva questions and every section of this topic.

  1. SGLT2 inhibitors
  2. Initial eGFR dip
  3. Non-steroidal MRA (finerenone)
  4. GLP-1 receptor agonists and risk-factor control
  5. Euglycaemic diabetic ketoacidosis
See the plans →
20

CKD progression — 4-pillar therapy

Open the full topic →
Fast Recap · 6 stops

CKD progression at a glance

Four drugs on top of lifestyle: ACEi or ARB, SGLT2 inhibitor, finerenone, GLP-1 agonist. Confirm true progression first; name every pillar with its trial.

  1. Progression Gradual eGFR decline; sudden rise is AKI-on-CKD.
  2. Pathophysiology Intraglomerular hypertension; mineralocorticoid-driven inflammation and fibrosis.
  3. Four pillars ACEi/ARB → SGLT2i → finerenone → GLP-1 agonist.
  1. 1

    Stop 1 · Assessment

    Progression vs AKI-on-CKD

    A creatinine jump after gastroenteritis is AKI-on-CKD, not progression.

    eGFR months → years K 6.2 ECG

    True progression

    Gradual eGFR decline over months to years.

    AKI-on-CKD

    Sudden rise after volume loss, disproportionate K, small kidneys.

    Urgent hospital assessmentHyperkalaemia
    ECG and repeat K at once; acute protocol:
    Restore: IV calcium if ECG changes · Redistribute: insulin-glucose, hourly glucose up to 6 h · Remove.
    ThenRehydration and drug holds
    Rehydrate after excluding obstruction; hold ACEi/ARB, SGLT2i, metformin.
    Early dialysis discussion if refractory; resume progression therapy after recovery.

    Viva case CKD3, oliguria after gastroenteritis, creatinine 2.0 → 5.0, K 6.2, small kidneys.

    Exam trap

    Oliguric AKI-on-CKD with K 6.2 is not a routine sick-day problem.

    Assessment of progression

    1

    History

    • NSAIDs, contrast, aminoglycosides
    • Volume loss, obstructive symptoms
    • Salt, protein, exercise, smoking
    2

    Examination and labs

    • BP, volume status
    • Serial eGFR and urine ACR
    • HbA1c, lipids, bicarbonate, urinalysis
    3

    Ultrasound

    • Small kidneys: chronic baseline
    • Exclude obstruction

    Reversible accelerants

    Uncontrolled hypertensionPoor glycaemic controlNephrotoxic drugsVolume depletionObstructionHigh proteinHigh saltSedentary / obesityMetabolic acidosis

    Viva case Diabetic CKD G3a, ACR 280 mg/g, HbA1c 8%, metformin + glimepiride.

    Memory hook

    “A slope is progression, a cliff is AKI.”

  2. 2

    Stop 2 · Treatment

    RAAS blockade and SGLT2 inhibition

    Subscribers only

Unlock the other 5 stops

Every drawing, memory hook and exam trap, the pocket check, the spoken answer, the viva questions and every section of this topic.

  1. Finerenone (nsMRA)
  2. GLP-1 agonist, metformin and lifestyle
  3. Sick-day rules and treatment alternatives
  4. Monitoring and RRT planning
See the plans →
46

Metabolic acidosis in CKD (bicarbonate/diet)

Open the full topic →
Fast Recap · 6 stops

CKD metabolic acidosis at a glance

Fewer nephrons make less ammonium: acid is retained with a normal gap. Consider treatment below 18; never push above normal.

  1. NH₄⁺ Nephron loss Less ammoniagenesis, less acid excreted.
  2. H⁺ H⁺ H⁺ H⁺ Normal-gap acidosis Acid retained; urine anion gap positive.
  3. 18 ULN bicarbonate Treat below 18 Never above the upper limit of normal.
  1. 1

    Stop 1 · Pathophysiology

    Renal ammoniagenesis

    Loss of nephron mass, not of regulation.

    Gln NH₄⁺ HCO₃⁻ lumen blood
    1. Proximal tubule

      Glutamine in via SNAT3 → NH₄⁺ + new HCO₃⁻ (glutaminase, PEPCK). NH₄⁺ out via NHE3 (angiotensin II).

    2. Thick ascending limb

      NKCC2 reabsorbs NH₄⁺: medullary pool.

    3. Collecting duct

      NH₃ via RhBg/RhCg buffers secreted H⁺.

    Acidosis and hypokalaemia stimulate every step. Bicarbonate falls once eGFR <60, most in G4–G5.
    Bicarbonate <22: 7.7% (diabetes) and 6.7% (no diabetes) at G3 A1; 38.3% and 35.9% at G5 A3.

    Memory hook
    ~1mmol/kg/day 60%NH₄⁺ 40%titratable

    Net acid excretion = NH₄⁺ + titratable acid − HCO₃⁻.

  2. 2

    Stop 2 · Diagnosis

    Anion gap assessment

    Subscribers only

Unlock the other 5 stops

Every drawing, memory hook and exam trap, the pocket check, the spoken answer, the viva questions and every section of this topic.

  1. Urine anion gap and urine ammonium
  2. Alkali therapy
  3. Dietary therapy
  4. Monitoring and follow-up
See the plans →
54

Anemia of CKD (ESA / HIF / iron)

Open the full topic →
Fast Recap · 6 stops

Anaemia of CKD at a glance

Too little EPO, too little usable iron. Iron first, ESA first-line, never hold Hb at 11.5.

  1. EPO deficiency Peritubular interstitial fibroblasts make less EPO.
  2. Iron restriction Hepcidin traps iron; correct iron first.
  3. 11.5 ESA ceiling Never maintain Hb 11.5 or above.
  1. 1

    Stop 1 · Diagnosis

    Definition and diagnostic work-up

    Confirm it, then exclude other causes before naming it.

    Hb <13.0 men <12.0 women g/dL · adults with CKD
    1

    Blood count

    CBC, film, reticulocytes: low = hypoproliferative marrow.

    2

    Haematinics

    Ferritin, TSAT, B12, folate.

    3

    Contributors

    PTH, calcium, phosphate, CRP; stool occult blood if indicated.

    • Hb checks: at least yearly G3, twice yearly G4, 3-monthly G5.
    • Not simple CKD anaemia: haptoglobin, LDH, LFT, paraprotein screen, TSH.
    • Ferritin <45: refer for a source of blood loss.
    • Non-CKD contributors: B12/folate deficiency, haemolysis, myelodysplasia, ACEi/ARB.
    Memory hook

    Iron-replete, no other cause: only then “anaemia of CKD”.

    Exam trap

    Serum EPO: not routine; a “normal” level can still be inadequate.

  2. 2

    Stop 2 · Investigations

    Iron status

    Subscribers only

Unlock the other 5 stops

Every drawing, memory hook and exam trap, the pocket check, the spoken answer, the viva questions and every section of this topic.

  1. Iron replacement
  2. Erythropoiesis-stimulating agents
  3. ESA hyporesponsiveness
  4. HIF-prolyl hydroxylase inhibitors
See the plans →
74

ESRD / CKD5 weight loss work-up (pre-dialysis)

Open the full topic →
Fast Recap · 5 stops

Weight loss in CKD 5 at a glance

Protein-energy wasting until proven otherwise; exclude cancer and infection first.

  1. over 10% Quantify the loss Over 10%: clinically significant.
  2. cancer? infection? Exclude other causes Loss unrelated to intake, EPO resistance, fever.
  3. HD? feed, then decide Feed, then decide Dietitian first; refractory wasting: start dialysis.
  1. 1

    Stop 1 · Assessment

    Nutritional assessment

    Percentage lost, over what time, then screen for PEW.

    5–10% >10% unintentional loss

    5–10% loss

    Above normal variation: earlier sign of undernutrition risk.

    Over 10% loss

    Clinically significant (CCN 2023).

    PEW screening: four categories

    1
    Biochemistry

    Albumin, CRP; cholesterol <150 mg/dL (3.8 mmol/L).

    2
    Body mass

    Weight trend, BMI, old weights.

    3
    Muscle mass

    Triceps skinfold, mid-arm muscle circumference, grip strength.

    4
    Dietary intake

    Diet history, food diary, appetite questionnaire.

    • Bloods: FBC, CRP, albumin, urea, bicarbonate, calcium, phosphate, PTH, glucose, thyroid, liver.
    • Low creatinine, phosphate, potassium, urea: low protein intake.
    • Examine: old weights, muscle and fat wasting, oedema, pallor, nodes, masses.

    SGA: reliable bedside tool (KDOQI: 7-point SGA in dialysis; alternatives MIS, DMS, GNRI). Prealbumin <300 mg/L: dialysis patients only.

    Exam trap

    BMI alone misleads: no muscle–fat split, no hydration. Albumin also falls with fluid, liver disease, inflammation.

  2. 2

    Stop 2 · Exclusion

    Differential diagnosis and malignancy red flags

    Subscribers only

Unlock the other 4 stops

Every drawing, memory hook and exam trap, the pocket check, the spoken answer, the viva questions and every section of this topic.

  1. Causes of protein-energy wasting
  2. Nutritional support
  3. Dialysis initiation and conservative kidney management
See the plans →
97

Conservative kidney management and dialysis withdrawal

Open the full topic →
Fast Recap · 6 stops

Conservative kidney management at a glance

A choice, not rationing: estimate prognosis, share the decision, care actively on every path.

  1. ? Prognosis Surprise question, frailty, KFRE.
  2. Shared decision Dialysis, trial or conservative care.
  3. Active supportive care Symptoms, planning, hospice.
  1. 1

    Stop 1 · Assessment

    Prognostic assessment

    Fix the crisis first; then estimate prognosis honestly.

    age >75 + 2 or more of: surprise “no” high comorbidity Karnofsky <40 albumin <2.5
    ?

    Surprise question

    Surprised by death in 6–12 months? “No” triggers advance care planning.

    F

    Clinical Frailty Scale

    1 very fit … 7 severely frail.

    K

    KFRE

    Kidney failure risk over 2 years, not death risk.

    RPA poor prognosis

    Age >75 + 2 of: surprise “no”, Charlson ≥8, Karnofsky <40, albumin <2.5 g/dL.

    Also poor

    Advanced dementia, terminal non-renal illness, frailty.
    Nursing-home starters: 58% dead at 1 year, 13% kept function.

    KFRE beyond 5 years overestimates (competing death); Grams model suits 4 years. No tool predicts the individual: state an estimate.

    Exam trap

    Age alone never decides; prognosis, function, comorbidity and values do.

  2. 2

    Stop 2 · Decision

    Shared decision-making

    Subscribers only

Unlock the other 5 stops

Every drawing, memory hook and exam trap, the pocket check, the spoken answer, the viva questions and every section of this topic.

  1. Comprehensive conservative care
  2. Symptom management
  3. Time-limited trial of dialysis
  4. Dialysis withdrawal and end-of-life care
See the plans →
103

CKD: KDIGO 2024 definition, CGA classification, screening, work-up and referral

Open the full topic →
Fast Recap · 7 stops

CKD definition and referral at a glance

Abnormal kidney structure or function for 3 months. Stage by Cause, GFR and Albuminuria; KFRE sorts referral.

  1. 1 2 3 months Chronicity Abnormal for at least 3 months.
  2. C G A cause GFR albumin CGA staging Cause, GFR category, albuminuria category.
  3. KFRE Risk and referral KFRE thresholds decide nephrology involvement.
  1. 1

    Stop 1 · Definition

    Definition and diagnostic criteria

    Structure or function abnormal ≥3 months, with health implications (KDIGO 2024).

    3 months GFR <60 or damage

    Decreased GFR

    <60 mL/min/1.73 m² (G3a–G5).

    Marker of damage (Table 1)

    Albuminuria: ACR ≥30 mg/g (≥3 mg/mmol).

    • Urine sediment abnormalities
    • Persistent haematuria
    • Tubular electrolyte disorders
    • Abnormal histology
    • Structural abnormality on imaging
    • History of kidney transplantation
    Memory hook

    “3 months, 2 tests”: eGFR and urine ACR, never creatinine alone.

    Exam trap

    G1 or G2 without any marker of damage is not CKD.

  2. 2

    Stop 2 · Detection

    Screening and confirmation of chronicity

    Subscribers only

Unlock the other 6 stops

Every drawing, memory hook and exam trap, the pocket check, the spoken answer, the viva questions and every section of this topic.

  1. Estimation of GFR and albuminuria
  2. CGA classification and risk heat map
  3. Aetiological work-up
  4. Kidney Failure Risk Equation
  5. Referral criteria and monitoring
See the plans →
104

Drug dosing in CKD and dialysis

Open the full topic →
Fast Recap · 7 stops

Drug dosing in CKD at a glance

Right GFR, full load, trimmed maintenance, and know what dialysis removes.

  1. GFR Which GFR? eGFRcr for most; cystatin for narrow windows.
  2. full load Full loading dose Set by volume of distribution.
  3. Dialysis removes some Small, unbound, low-Vd drugs: give after.
  1. 1

    Stop 1 · Assessment

    GFR estimation for drug dosing

    Pick the estimate to fit the patient (KDIGO 2024, 4.2.2–4.2.5).

    eGFRcr + cystatin non-indexed levels C-G: not in dialysis stable creatinine only
    Most drugs
    Validated eGFRcr.
    Narrow window
    eGFRcr-cys or measured GFR.
    Extreme size
    Non-indexed eGFR = indexed × BSA / 1.73.
    AKI, unstable
    Creatinine lags: review daily, use levels.

    Cockcroft-Gault invalid: dialysis, creatinine >350 µmol/L, age <15 or >90, pregnancy, amputees, severe wasting. Use ideal weight if >15% over.

    Exam trap

    Trimethoprim, cimetidine, cefoxitin raise creatinine without lowering GFR.

  2. 2

    Stop 2 · Pharmacokinetics

    Loading and maintenance doses

    Subscribers only

Unlock the other 6 stops

Every drawing, memory hook and exam trap, the pocket check, the spoken answer, the viva questions and every section of this topic.

  1. Drug removal by dialysis
  2. Antimicrobial dosing
  3. Anticoagulants in CKD and dialysis
  4. Extracorporeal treatment of poisoning (EXTRIP)
  5. Toxic alcohol poisoning
See the plans →
Home All Topics Contact Us Terms of Service Privacy Policy Refund Policy Facebook YouTube Monawib

Tools: Nephrology tools · Radiology

Disclaimer: NephroApp is an independent educational platform and is not affiliated with, endorsed by, or sponsored by any licensing authority, examination provider, or textbook publisher. The MCQ Bank provides exam-style practice for educational purposes.

Nephroapp© 2026. All rights reserved.

Made with by Dr. Hossam Abohassan